ATE373483T1 - Zusammensetzung zur behandlung von prostatakrebs - Google Patents

Zusammensetzung zur behandlung von prostatakrebs

Info

Publication number: ATE373483T1
Authority: AT; Austria
Prior art keywords: prostate cancer; composition; treating prostate; living mammal; glycosidase
Prior art date: 1999-10-28

Application number

AT00989699T

Other languages

English (en)

Inventor

Muharrem Gokcen

Original Assignee

Immunolytics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-10-28

Filing date

2000-10-25

Publication date

2007-10-15

2000-10-25 Application filed by Immunolytics Inc filed Critical Immunolytics Inc

2007-10-15 Application granted granted Critical

2007-10-15 Publication of ATE373483T1 publication Critical patent/ATE373483T1/de

Links

206010060862 Prostate cancer Diseases 0.000 title abstract 5
208000000236 Prostatic Neoplasms Diseases 0.000 title abstract 5
239000000203 mixture Substances 0.000 title abstract 4
238000000034 method Methods 0.000 abstract 4
241000124008 Mammalia Species 0.000 abstract 3
-1 for example Proteins 0.000 abstract 3
BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 abstract 2
102000029816 Collagenase Human genes 0.000 abstract 2
108060005980 Collagenase Proteins 0.000 abstract 2
108010031186 Glycoside Hydrolases Proteins 0.000 abstract 2
102000005744 Glycoside Hydrolases Human genes 0.000 abstract 2
229910001424 calcium ion Inorganic materials 0.000 abstract 2
229960002424 collagenase Drugs 0.000 abstract 2
AXMJGXMRGDCRND-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[4-(2,4,4-trimethylpentan-2-yl)cyclohexyl]oxyethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CC(C)(C)CC(C)(C)C1CCC(OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO)CC1 AXMJGXMRGDCRND-UHFFFAOYSA-N 0.000 abstract 1
108090000371 Esterases Proteins 0.000 abstract 1
CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 abstract 1
229930182566 Gentamicin Natural products 0.000 abstract 1
108010003272 Hyaluronate lyase Proteins 0.000 abstract 1
102000009066 Hyaluronoglucosaminidase Human genes 0.000 abstract 1
102000004882 Lipase Human genes 0.000 abstract 1
108090001060 Lipase Proteins 0.000 abstract 1
239000004367 Lipase Substances 0.000 abstract 1
101710163270 Nuclease Proteins 0.000 abstract 1
108091005804 Peptidases Proteins 0.000 abstract 1
108010001014 Plasminogen Activators Proteins 0.000 abstract 1
102000001938 Plasminogen Activators Human genes 0.000 abstract 1
239000004365 Protease Substances 0.000 abstract 1
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 abstract 1
108010023197 Streptokinase Proteins 0.000 abstract 1
230000003213 activating effect Effects 0.000 abstract 1
239000003242 anti bacterial agent Substances 0.000 abstract 1
230000003115 biocidal effect Effects 0.000 abstract 1
229960002518 gentamicin Drugs 0.000 abstract 1
229960002773 hyaluronidase Drugs 0.000 abstract 1
238000001727 in vivo Methods 0.000 abstract 1
235000019421 lipase Nutrition 0.000 abstract 1
239000002736 nonionic surfactant Substances 0.000 abstract 1
229940127126 plasminogen activator Drugs 0.000 abstract 1
229960005202 streptokinase Drugs 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Inorganic Chemistry (AREA)
Urology & Nephrology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Enzymes And Modification Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Plant Substances (AREA)
Saccharide Compounds (AREA)

AT00989699T 1999-10-28 2000-10-25 Zusammensetzung zur behandlung von prostatakrebs ATE373483T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US09/428,375 US6428785B1 (en)	1999-10-28	1999-10-28	Method and composition for treating prostate cancer

Publications (1)

Publication Number	Publication Date
ATE373483T1 true ATE373483T1 (de)	2007-10-15

Family

ID=23698630

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT00989699T ATE373483T1 (de)	1999-10-28	2000-10-25	Zusammensetzung zur behandlung von prostatakrebs

Country Status (9)

Country	Link
US (2)	US6428785B1 (de)
EP (1)	EP1242110B1 (de)
JP (1)	JP2003513931A (de)
CN (1)	CN1176714C (de)
AT (1)	ATE373483T1 (de)
AU (1)	AU2617901A (de)
CA (1)	CA2389176A1 (de)
DE (1)	DE60036490T2 (de)
WO (1)	WO2001034176A1 (de)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7595199B1 (en) *	1998-07-31	2009-09-29	Max-Planck-Gesellschaft zur Förderung der Wissenchaften e.V.	Method of detecting amyloid-like fibrils or protein aggregates
ES2424348T3 (es) *	2002-06-24	2013-10-01	Incept, Llc	Cargas y métodos para desplazar tejidos para mejorar los resultados radiológicos
AU2003298972A1 (en) *	2003-07-14	2005-02-04	Dmitry Dmitrievich Genkin	Method for treating oncological, virulent and somatic diseases, method for controlling treatment efficiency, pharmaceutical agents and composition for carrying out said treatment
WO2006130034A1 (fr) *	2005-04-25	2006-12-07	Dmitry Dmitrievich Genkin	Procede pour prolonger la duree de vie d'animaux ou de l'humain
US8388951B2 (en)	2003-07-14	2013-03-05	Cls Therapeutics Limited	Method for treating systemic DNA mutation disease
US9248166B2 (en)	2003-07-14	2016-02-02	Cls Therapeutics Limited	Method for treating oncological diseases
US8431123B2 (en) *	2003-07-14	2013-04-30	Cls Therapeutics Limited	Method for treating systemic bacterial, fungal and protozoan infection
US8710012B2 (en) *	2003-07-14	2014-04-29	Cls Therapeutics Limited	Method for treating oncological diseases
GB2408207A (en) *	2003-11-24	2005-05-25	Johnson & Johnson Medical Ltd	Wound dressing for the controlled release of therapeutic agents comprising also an inhibitor of a protease enzyme & a linker group cleavable by such an enzyme
MXPA03011987A (es) *	2003-12-19	2005-06-23	Osio Sancho Alberto	Metodo para el tratamiento de la presbicia induciendo cambios en el poder y fisiologia corneal.
WO2005080589A1 (en) *	2004-02-19	2005-09-01	Bayer Healthcare Ag	Diagnostics and therapeutics for diseases associated with kallikrein 3 (klk3)
WO2005097149A2 (en) *	2004-04-09	2005-10-20	Nicholas Piramal India Limited	Herbal extract for renal disorders
JP2008505853A (ja)	2004-04-13	2008-02-28	クインテセンスバイオサイエンシーズインコーポレーティッド	細胞傷害性薬剤としての非天然のリボヌクレアーゼ複合体
ES2509872T3 (es)	2005-03-03	2014-10-20	Allergan, Inc.	Procedimientos para obtener una toxina clostrídica
JP3989936B2 (ja) *	2005-04-07	2007-10-10	進須永	抗腫瘍剤及び新規ｄｎアーゼ
CA2633980A1 (en) *	2005-12-29	2007-07-12	Anthrogenesis Corporation	Improved composition for collecting and preserving placental stem cells and methods of using the composition
US8840882B2 (en) *	2006-06-23	2014-09-23	Quintessence Biosciences, Inc.	Modified ribonucleases
WO2008010991A2 (en)	2006-07-17	2008-01-24	Quintessence Biosciences, Inc.	Methods and compositions for the treatment of cancer
US20080027554A1 (en) *	2006-07-31	2008-01-31	Talmadge Karen D	Kit and methods of treatment of an intervertebral disc
US8871200B2 (en) *	2006-11-28	2014-10-28	Cls Therapeutics Limited	Method for treating human diseases associated with an increased deoxyribonucleic acid content in extracellular spaces of tissues and a medicinal preparation for carrying out said method
CA2678038C (en)	2007-02-15	2016-10-11	Allergan, Inc.	Use of botulinum toxin and enzymes for treating bladder or prostate disorders, or hyperhydrosis
CN101313926B (zh) *	2007-05-30	2012-12-26	中央研究院	转录调控物组合物
PL2187965T3 (pl)	2007-08-17	2020-05-18	Purdue Research Foundation	Koniugaty wiążący psma ligand-łącznik i sposoby ich zastosowania
WO2009048909A1 (en) *	2007-10-08	2009-04-16	Quintessence Biosciences, Inc.	Compositions and methods for ribonuclease-based therapies
CA2734446C (en)	2008-08-22	2017-06-20	Anthrogenesis Corporation	Methods and compositions for treatment of bone defects with placental cell populations
BRPI0920743A2 (pt)	2008-10-01	2016-09-20	Quintessence Biosciences Inc	ribonucleases terapeuticas
WO2010138918A1 (en) *	2009-05-29	2010-12-02	Pacira Pharmaceuticals, Inc.	Hyaluronidase as an adjuvant for increasing the injection volume and dispersion of large diameter synthetic membrane vesicles containing a therapeutic agent
CA3149284A1 (en)	2009-12-15	2011-07-14	Incept, Llc	Implants and biodegradable fiducial markers
US9951324B2 (en)	2010-02-25	2018-04-24	Purdue Research Foundation	PSMA binding ligand-linker conjugates and methods for using
MX2012011543A (es)	2010-04-08	2013-05-06	Anthrogenesis Corp	Tratamiento de sarcoidosis empleando celulas madre placentarias.
US8557777B2 (en)	2010-07-09	2013-10-15	The Board Of Trustees Of The University Of Illinois	Methods for treating cancer using prostate specific antigen and tumor endothelial marker peptides
WO2012006634A2 (en) *	2010-07-09	2012-01-12	The Board Of Trustees Of The University Of Illiniois	Prostate specific antigen (psa) peptide therapy
US8969315B2 (en)	2010-12-31	2015-03-03	Anthrogenesis Corporation	Enhancement of placental stem cell potency using modulatory RNA molecules
WO2012109387A1 (en)	2011-02-08	2012-08-16	Halozyme, Inc.	Composition and lipid formulation of a hyaluronan-degrading enzyme and the use thereof for treatment of benign prostatic hyperplasia
JP6104896B2 (ja)	2011-06-01	2017-03-29	アントフロゲネシスコーポレーション	胎盤幹細胞を使用する疼痛の治療
WO2013091657A1 (en) *	2011-12-22	2013-06-27	Herlev Hospital	Therapeutic applications of calcium electroporation to effectively induce tumor necrosis
DK2883104T3 (da)	2012-08-10	2024-07-29	Osio Corp D/B/A Yolia Health	Anvendelse af kontaktlinse ved behandling af en ofthalmologisk lidelse
EA201590783A1 (ru)	2012-11-15	2015-11-30	Эндосайт, Инк.	Конъюгаты для доставки лекарственных средств и способы лечения заболеваний, вызванных клетками, экспрессирующими psma
EP3456700A1 (de)	2013-10-18	2019-03-20	Deutsches Krebsforschungszentrum	Markierte inhibitoren des prostataspezifischen membranantigens (psma), deren verwendung als kontrastmittel und pharmazeutika zur behandlung von prostatakrebs
EP3533473A3 (de)	2013-11-14	2019-12-18	Endocyte, Inc.	Verbindungen für positronenemissionstomografie
CZ307195B6 (cs) *	2013-11-18	2018-03-14	František Trnka	Farmaceutická kompozice obsahující směs proenzymů a enzymů
WO2015140802A2 (en) *	2014-03-20	2015-09-24	Technion Research & Development Foundation Limited	Delivery system comprising a proteolytic enzyme or effector thereof for use in a method for oral treatment and uses thereof
US12144519B2 (en)	2014-04-03	2024-11-19	Corbin Clinical Resources, Llc	Transperineal prostate biopsy and treatment methods
US10743909B2 (en)	2014-04-03	2020-08-18	Corbin Clinical Resources, Llc	Transperineal prostate biopsy device, systems, and methods of use
US10064681B2 (en)	2014-04-03	2018-09-04	Corbin Clinical Resources, Llc	Method, system, and device for planning and performing, guided and free-handed transperineal prostate biopsies
US10617743B2 (en)	2014-06-19	2020-04-14	Cls Therapeutics Limited	Method to improve safety and efficacy of anti-cancer therapy
GB2528304B (en) *	2014-07-17	2020-05-13	Cambridge Univ Hospitals Nhs Foundation Trust	Perineal prostate biopsy apparatus
WO2016025922A1 (en) *	2014-08-14	2016-02-18	Dana-Farber Cancer Institute, Inc.	Coated particles for drug delivery
CN105477627B (zh) *	2014-09-19	2021-04-30	山东蓝金生物工程有限公司	治疗前列腺癌的组合物及其用途
KR101683635B1 (ko)	2014-12-29	2016-12-09	가천대학교 산학협력단	락테이트 금속염을 포함하는 암 치료용 약학 조성물
US10188759B2 (en)	2015-01-07	2019-01-29	Endocyte, Inc.	Conjugates for imaging
ES2799515T3 (es)	2015-05-22	2020-12-18	Dmitry Dmitrievich Genkin	ADN extracelular como una diana terapéutica en la neurodegeneración
WO2017074257A1 (en) *	2015-10-26	2017-05-04	Nanyang Technological University	Non-viable derivatives of clostridium sporogenes as anti-cancer therapeutic agents
CN105255825B (zh) *	2015-11-16	2019-07-19	广州赛莱拉干细胞科技股份有限公司	一种跟腱来源肌腱干细胞原代分离消化液及分离方法
AU2019209770B2 (en)	2018-01-16	2025-07-31	Cls Therapeutics Limited	Treatment of diseases by liver expression of an enzyme which has a deoxyribonuclease (DNase) activity
WO2019145950A1 (en)	2018-01-23	2019-08-01	Technion Research & Development Foundation Limited	Collagenase loaded liposomes for enhancing drug delivery
CN112368024A (zh)	2018-04-17	2021-02-12	恩多塞特公司	治疗癌症的方法
EP3698806A1 (de) *	2019-02-19	2020-08-26	Fundacion Instituto De Investigacion Sanitaria Fundacion Jimenez Diaz	Chemisches skalpell
CN114096264B (zh)	2019-05-20	2025-03-14	因多塞特股份有限公司	制备psma缀合物的方法
CN111705051A (zh) *	2020-07-28	2020-09-25	金紫晶(南京)生物医药技术有限公司	一种复合消化酶及复合消化酶冻干粉
CN112941009B (zh) *	2021-02-22	2024-03-01	新格元(南京)生物科技有限公司	一种ffpe样本预处理液及从ffpe样本中分离单细胞的方法
CN115671267A (zh) *	2021-07-23	2023-02-03	上海宝济药业有限公司	一种皮下抗生素药物组合物
CN117258047B (zh) *	2023-10-12	2024-06-18	成都世联康健生物科技有限公司	一种猪牙髓组织脱细胞外基质水凝胶及其制备方法和应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4524065A (en)	1983-08-04	1985-06-18	Bio-Specifics N.V.	Method for the prevention and treatment of scars with enzymes
US4645668A (en)	1983-08-04	1987-02-24	Biospecifics, Nv	Method for the prevention and treatment of scars with enzymes
US4678668A (en)	1985-10-28	1987-07-07	Md Associates	Method of reducing soft tissue swelling and pain
US4978332A (en)	1987-09-28	1990-12-18	Matrix Pharmaceutical, Inc.	Treatments employing vasoconstrictive substances in combination with cytotoxic agents for introduction into cellular lesion areas
US5116615A (en)	1989-01-27	1992-05-26	Immunolytics, Inc.	Method for treating benign prostatic hypertrophy
HK1003981A1 (en) *	1989-01-27	1998-11-13	Immunolytics, Inc.	Composition and method for treating benign prostatic hypertrophy
US5162115A (en)	1989-05-09	1992-11-10	Pietronigro Dennis D	Antineoplastic solution and method for treating neoplasms
US5051257A (en)	1989-05-09	1991-09-24	Pietronigro Dennis D	Antineoplastic solution and method for treating neoplasms
US5958406A (en) *	1994-11-22	1999-09-28	Phairson Medical Inc.	Acne treatment with multifunctional enzyme
US5422261A (en)	1993-04-16	1995-06-06	Baxter International Inc.	Composition containing collagenase and chymopapain for hydrolyzing connective tissue to isolate cells
JPH09508892A (ja)	1993-11-17	1997-09-09	マサチューセッツインスティテュートオブテクノロジー	ヘパリナーゼを用いる血管形成の阻害方法
CA2189646C (en)	1994-06-24	1999-05-25	Francis E. Dwulet	A purified mixture of collagenases and two other proteases obtained from clostridium histolyticum
US5658730A (en)	1994-12-23	1997-08-19	Ctrc Research Foundation	Methods of human prostate cancer diagnosis
US5854206A (en)	1995-08-25	1998-12-29	Corixa Corporation	Compounds and methods for treatment and diagnosis of prostate cancer
AU7130696A (en)	1995-09-19	1997-04-09	Schering Aktiengesellschaft	Combination of beta-interferon for the treatment of prostate cancer
US5783182A (en)	1996-01-30	1998-07-21	Baylor College Of Medicine	Method for identifying metastatic sequences
US5780435A (en)	1995-12-15	1998-07-14	Praecis Pharmaceuticals Incorporated	Methods for treating prostate cancer with LHRH-R antagonists
US5989888A (en)	1996-01-24	1999-11-23	Roche Diagnostics Corporation	Purified mixture of collagenase I, collagenase II and two other proteases
US5716541A (en)	1996-09-23	1998-02-10	Bayer Corporation	Azeotrope-like compositions of 1,1,1,3,3 pentafluoropropane and tetramethylsilane
US5830741A (en)	1996-12-06	1998-11-03	Boehringer Mannheim Corporation	Composition for tissue dissociation containing collagenase I and II from clostridium histolyticum and a neutral protease

1999
- 1999-10-28 US US09/428,375 patent/US6428785B1/en not_active Expired - Fee Related
2000
- 2000-10-25 JP JP2001536173A patent/JP2003513931A/ja active Pending
- 2000-10-25 WO PCT/US2000/041562 patent/WO2001034176A1/en not_active Ceased
- 2000-10-25 EP EP00989699A patent/EP1242110B1/de not_active Expired - Lifetime
- 2000-10-25 AU AU26179/01A patent/AU2617901A/en not_active Abandoned
- 2000-10-25 CN CNB008149208A patent/CN1176714C/zh not_active Expired - Fee Related
- 2000-10-25 AT AT00989699T patent/ATE373483T1/de not_active IP Right Cessation
- 2000-10-25 DE DE60036490T patent/DE60036490T2/de not_active Expired - Fee Related
- 2000-10-25 CA CA002389176A patent/CA2389176A1/en not_active Abandoned
2002
- 2002-01-22 US US10/055,063 patent/US6913744B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
DE60036490D1 (de)	2007-10-31
CA2389176A1 (en)	2001-05-17
US6428785B1 (en)	2002-08-06
EP1242110A1 (de)	2002-09-25
US20020106359A1 (en)	2002-08-08
WO2001034176A1 (en)	2001-05-17
CN1384754A (zh)	2002-12-11
JP2003513931A (ja)	2003-04-15
US6913744B2 (en)	2005-07-05
US20020061300A1 (en)	2002-05-23
AU2617901A (en)	2001-06-06
DE60036490T2 (de)	2008-06-19
EP1242110B1 (de)	2007-09-19
CN1176714C (zh)	2004-11-24

Legal Events

Date	Code	Title	Description
2008-03-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DE60036490D1 (de)	2007-10-31	Zusammensetzung zur behandlung von prostatakrebs
ATE255418T1 (de)	2003-12-15	Neurotoxine zur behandlung von pankreatischen krankheiten
MEP26808A (en)	2010-06-10	The use of substituted azetidinone compounds for the treatment of sitosterolemia
TR199801151T2 (xx)	1998-08-21	Trombin inhibit�r� �n ila�lar.
DK0719154T3 (da)	2001-11-26	Aktiveret faktor VIII som terapeutisk middel og metode til behandling af faktor VIII-mangel
ATE543509T1 (de)	2012-02-15	Material und verfahren zur förderung der reparatur von nervengewebe
ATE518540T1 (de)	2011-08-15	Beta-lactam verbindung enthaltende neurotherapeutische zusammensetzung
DE60042153D1 (de)	2009-06-18	Pharmauzetisch zusammensetzung nitratenquelle und ansäuerungsmitteln enthaltende zur behandlung von offenen wunden und verbrennungen
MX9606386A (es)	1997-03-29	Agentes que afectan la hemostasis trombotica.
ATE121946T1 (de)	1995-05-15	Zusammensetzung und verfahren für die behandlung gutartiger prostata-hypertrophie.
DE60139078D1 (de)	2009-08-06	Plasminogen aktivator zur verhinderung von horn- und subepithelialeintrübung nach laser-sehkraftkorrektur-chirurgie
EP1226109A4 (de)	2005-01-26	Phenylamin-carbonsäure-verbindungen und zubereitungen zur verabreichung von wirkstoffen
EP1098642A4 (de)	2004-08-18	Verfahren zur behandlung von zustanden moduliert durch lactosylceramiden
ES2082198T3 (es)	1996-03-16	Inhibidores de esteroide-sulfatasa.
MXPA02009904A (es)	2004-09-06	Derivados de apomorfina y metodos para su uso.
HK1049115A1 (zh)	2003-05-02	治療過敏性失調的成分和方法
ATE385807T1 (de)	2008-03-15	Pharmazeutische verbindung und methoden zur behandlung von menschlichen karzinomen mittels arginin entzug
ATE255904T1 (de)	2003-12-15	Fibrin-/fibrinogen-abbau und gerinsel-auflösung durch eine fibrinolytische matrix- metallproteinase
ATE368455T1 (de)	2007-08-15	Verwendung von (+)-tramadol, o-demethyltramadol, o-desmethyl-n-mono-desmethyl-tramadol zur therapie der harninkontinenz
ATE277943T1 (de)	2004-10-15	Trypsininhibitoren
AU5170400A (en)	2000-12-18	Topical application of muscarinic and opioid agents for treatment of tinnitus
ATE230609T1 (de)	2003-01-15	Verfahren zur behandlung von entzündungen und zusammensetzungen dafür
ATE493147T1 (de)	2011-01-15	Pharmazeutische zusammensetzungen und methoden nützlich zur behandlung von krebs oder leberfibrose
ATE321045T1 (de)	2006-04-15	Methoden und zusammensetzungen zur behandlung von schmerzen
ES2284528T3 (es)	2007-11-16	Utilizacion de elastasa para abrir arterias y venas obstruidas.